Aktis Oncology, Inc. (AKTS) vs Kura Oncology, Inc. (KURA)
A side-by-side comparison of Aktis Oncology, Inc. and Kura Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.41HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
KURA
Kura Oncology, Inc.
$10.40HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Total return — AKTS vs KURA
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)KURA +6.5% (+6.5%/yr)KURA compounded faster over this window
AKTS KURA
AKTS vs KURA: by the numbers
- •AKTS is the larger company ($983M vs $923M market cap).
- •Both run net losses; KURA's is the smaller (-384.30% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | KURA |
|---|---|---|
| P/S ratio | 97.76 | 11.96 |
| P/B ratio | 2.03 | 19.06 |
Profitability
| Metric | AKTS | KURA |
|---|---|---|
| Gross margin | 100.00% | 94.73% |
| Operating margin | -1149.52% | -449.94% |
| Net margin | -727.04% | -384.30% |
| ROE | -15.09% | -612.78% |
| ROIC | -16.54% | -67.13% |
Growth (annualized)
| Metric | AKTS | KURA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -10.73% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.